Neurocrine Biosciences reported $972.8M in Current Assets for its fourth fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Assets Change
Abbvie ABBV:US $ 26509M 1419M
Acadia Pharmaceuticals ACAD:US $ 542.22M 75.6M
Acorda Therapeutics ACOR:US $ 80.46M 21.7M
Agios Pharmaceuticals AGIO:US $ 975.14M 89.09M
Alnylam Pharmaceuticals ALNY:US $ 2589.68M 218.9M
Amgen AMGN:US $ 18520M 865M
Aptinyx Inc APTX:US $ 106.53M 8.22M
Biogen BIIB:US $ 7915.9M 59.4M
Biomarin Pharmaceutical BMRN:US $ 2394.02M 119.64M
Cytokinetics CYTK:US $ 623.53M 87.85M
Dynavax Technologies DVAX:US $ 940.52M 32.01M
Enanta Pharmaceuticals ENTA:US $ 341.87M 14.91M
Exelixis EXEL:US $ 1842.74M 8M
Halozyme Therapeutics HALO:US $ 988.69M 62.4M
IONIS PHARMACEUT IONS:US $ 2253.12M 91.92M
Nektar Therapeutics NKTR:US $ 795.58M 190.55M
Prothena PRTA:US 555.62M 29.19M
Teva Pharmaceutical TEVA:IT 12.45B 122M
Ultragenyx Pharmaceutical RARE:US $ 707.52M 149.08M
Xoma XOMA:US $ 89.61M 7.36M